• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Guardant Health Announces Definitive Agreement to Acquire Bellwether Bio

    Jocelyn Aspa
    Mar. 27, 2019 08:58AM PST
    Pharmaceutical Investing

    Guardant Health (NASDAQ:GH) has announced it has entered into an agreement to acquire Bellwether Bio with the transaction expected to close in April 2019. As quoted in the press release: The Bellwether Bio team will join Guardant Health to further advance its early detection product pipeline.  The team includes Jay Shendure, MD, PhD, who will …

    Guardant Health (NASDAQ:GH) has announced it has entered into an agreement to acquire Bellwether Bio with the transaction expected to close in April 2019.

    As quoted in the press release:

    The Bellwether Bio team will join Guardant Health to further advance its early detection product pipeline.  The team includes Jay Shendure, MD, PhD, who will act as a scientific advisor to Guardant Health. His lab’s work on the epigenomics of cell-free DNA, specifically with respect to nucleosome positioning and fragmentomics, was described in a landmark Cell publication in 2016 co-authored by Bellwether Bio CTO Matthew Snyder, PhD.

    “We are excited to welcome the Bellwether team and believe they will enhance our product pipeline as we seek to expand precision oncology to earlier stages of disease,” said Guardant Health Co-Founder and President AmirAli Talasaz, PhD.  “Our early research has shown the strong potential impact of incorporating biologically-relevant epigenomic information on the clinical performance of blood tests for early stage cancer detection.”

    At the AACR annual meeting in Atlanta on March 31, 3pm, investigators from Guardant Health and the Samsung Medical Center will report results from a pilot study (abstract #916) of Guardant’s LUNAR assay in early stage cancer. The study demonstrates that addition of epigenomics to the assay can potentially lead to significant improvements in sensitivity for stage I and II colorectal cancer.

    “Guardant has demonstrated remarkable progress toward its goal,” Bellwether Bio CEO Rahul Shendure said. “I am proud of the groundbreaking work the Bellwether team has accomplished to date and believe that joining Guardant’s efforts will speed their path even further.”

    Click here to read the full press release.

    pharmaceutical investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×